Skip to main content
Clinical Trials/CTRI/2023/08/056035
CTRI/2023/08/056035Not yet recruitingPhase 3

Efficacy of Yavanishadavadi Vati with Drakhsavaleha as an adjunct therapy in the management of Rajyakshma ( Multi Drug Resistant (MDR) Pulmonary Tuberculosis) - An open label randomized controlled trial - NA

Institute of Teaching and Research in Ayurveda Jamnagar0 sites0 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 3
Status
Not yet recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • 1.Patients willing to comply with all study procedures and availability for the duration of the study.
  • 2.Patients having Rifampsin resistance or Isoniazid resistance.
  • 3.Patients with primary and acquired resistance to MTB.

Exclusion Criteria

  • 1.Patients having uncontrolled cardiac, renal, hepatic disease, HIV-AIDS, malignancy, cancer and other associated lung disease.
  • 2.Pregnant and lactating women.
  • 3.Patients who are getting first line (primary DS PTB) Anti tubercular treatment.
  • 4.MDR PTB patients whose acute illness required intensive care.
  • 5.Patient who are intolerated to ATD regimen
  • 6.Extra pulmonary PTB patients will be excluded
  • 7.Patients having both Rifampsin and Isoniazid or any other drug resistance from the ATD regimen.
  • 8.Patients with longer (18-24 months) ATD regimen.

Investigators

Sponsor
Institute of Teaching and Research in Ayurveda Jamnagar

Similar Trials